6404 RESULTS
Sort By:
Are you curious about trying iPS cell lines to model the disease you care about? Intrigued but nebulous on where the field is at? Ready to grow an iPS line but not sure where to turn? Read Madolyn Rogers's four-part series to learn all about who does
When the first human genome sequence was finished in 2003, it quickly became clear that its seemingly unending stream of letters was not enough to comprehend what makes people tick. All the moving parts that bring the DNA code to life needed to be underst
In the absence of truly effective treatments, and in the presence of a rapidly growing, dementia-prone population of elders, it's perhaps no surprise that people are increasingly open to products claiming even the slightest hint of promise, however u
Move over, genome, transcriptome, proteome. The latest ome aims to map every metabolite linked to human health and disease. Metabolomics, although still a nascent field, offers hope for biomarkers and treatments in neurodegenerative disease. The field
As populations age worldwide and the number of people with dementia is set to soar over the next few decades, a crisis in eldercare looms. At the same time, the use of personal technology—smartphones, tablets, wearable monitors—is exploding. Can technolog
Did you know that if you had a spinal tap for a cerebrospinal fluid-based Alzheimer's diagnosis in Boston, Stockholm, London, or San Diego, the readout would likely be different in each place? And different again this year and next? That's a pro
Researchers have tied sleep to clearance of waste products such as excess Aβ. New research suggests this clearance may be driven by a change in the extracellular ion composition, which swells the interstitial fluid. Other work finds an essential role for
In the Finnish city of Kuopio, neurosurgeons collaborate with neurophysiologists and molecular and cellular biologists to make frontal cortex, dura, intraventricular CSF, skin, fat, and other tissue from hydrocephalus patients available for research purpo
CRISPR Gene Editing—Poised to Revolutionize Neuroscience? Neuroscientists Probe CRISPR Transgenics and Treatment Paradigms
Two weeks after the FDA gave the nod to aducanumab, the aftershocks continue to reverberate. Critics are lambasting the agency, three members of its advisory committee resigned, and the drug’s cost has ignited calls for pricing reform. Meanwhile, Alzheime
A $40 million multicenter biomarker study for Parkinson disease progression is off and running, with enrollment underway at 10 of 18 sites in the U.S. and Europe. In design and operation, the Parkinson's Progression Markers Initiative (PPMI) follow
The European Union is banking on big returns from nanotechnology in the fight against AD. European Union Throws Megabucks at Nanomedicine EU Consortium Applies Nanotechnology to Study AD
If you find it hard to keep up with Facebook, LinkedIn, and other social networks, spare a thought for the brain. With 100 to 500 trillion synaptic connections, the human brain dwarfs all of them. How do those connections work to formulate thought, recall
If you listen to National Public Radio, watch TV, or surf the Web, chances are you have come across commercials enticing you to “improve your memory” and “unlock your inner genius” with “brain training developed by neuroscientists.” In search of solid ev
U.S. guidelines for assessing Alzheimer's disease (AD) neuropathology are getting a much-needed facelift. The existing ones, in place since 1997, had fallen out of step with the current understanding of AD as a disease with a long preclinical stage.
